Clinical Trial Update: Efficacy and Safety of Inhaled NC-107 As Compared to Placebo After 4 Weeks of Treatment in Patients with Anxiety [EARLY_Phase 1]

View source ↗

Summary

This early Phase 1 trial compares inhaled NC-107 to placebo for 4 weeks in patients with Generalized Anxiety Disorder, assessing efficacy and safety. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• NC-107 (NC-107)

Snippet

Sponsor: Trinity Hypertension & Metabolic Research Institute | Conditions: Generalized Anxiety Disorder | EARLY_Phase 1 | Status: NOT_YET_RECRUITING